Literature DB >> 32211447

Assessing Hepatitis B Reactivation Risk With Rituximab and Recent Intravenous Immunoglobulin Therapy.

Claire Dysart1, Karine Rozenberg-Ben-Dror2, Mariscelle Sales3.   

Abstract

Hepatitis B reactivation (HBR) is a complication of immunosuppression associated with significant morbidity and mortality. To further complicate interpretation of hepatitis B serologies, false positivity can occur in patients with recent intravenous immunoglobulin exposure. This scenario is not well recognized and may lead to inappropriate prescribing of HBR prophylaxis. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.

Entities:  

Keywords:  hepatitis B; immunoglobulin; reactivation; rituximab; serologies

Year:  2020        PMID： 32211447      PMCID： PMC7085305          DOI： 10.1093/ofid/ofaa080

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN： 2328-8957            Impact factor:   3.835


  10 in total

Review 1.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

Review 2.  American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  K Rajender Reddy; Kimberly L Beavers; Sarah P Hammond; Joseph K Lim; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

3.  Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia.

Authors:  Donald M Arnold; Mark A Crowther; Ralph M Meyer; Julie Carruthers; Julie Ditomasso; Nancy M Heddle; Anne McLeod; John G Kelton
Journal:  Transfusion       Date:  2010-12       Impact factor: 3.157

4.  False positive hepatitis B virus core and surface antibodies due to intravenous immunoglobulin.

Authors:  Nicola Benwell; Peter Boan; Edward Raby; Ben McGettigan
Journal:  Intern Med J       Date:  2017-01       Impact factor: 2.048

Review 5.  Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review.

Authors:  Yun-Fan Liaw
Journal:  Hepatology       Date:  2011-06       Impact factor: 17.425

6.  Medication-use evaluation with a Web application.

Authors:  Muriel Burk; Von Moore; Peter Glassman; Chester B Good; Thomas Emmendorfer; Thomas C Leadholm; Francesca Cunningham
Journal:  Am J Health Syst Pharm       Date:  2013-12-15       Impact factor: 2.637

7.  Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review.

Authors:  Huifang Lu; Anna S Lok; Carla L Warneke; Sairah Ahmed; Harrys A Torres; Fernando Martinez; Maria E Suarez-Almazor; Jessica T Foreman; Alessandra Ferrajoli; Jessica P Hwang
Journal:  Lancet Haematol       Date:  2018-10       Impact factor: 18.959

8.  Transmission of Hepatitis B Core Antibody and Galactomannan Enzyme Immunoassay Positivity via Immunoglobulin Products: A Comprehensive Analysis.

Authors:  Isobel Ramsay; Rebecca L Gorton; Mauli Patel; Sarita Workman; Andrew Symes; Tanzina Haque; Dianne Irish; Suranjith L Seneviratne; Siobhan O Burns; Emmanuel Wey; David M Lowe
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

9.  Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.

Authors:  Jessica P Hwang; Mark R Somerfield; Devena E Alston-Johnson; Donna R Cryer; Jordan J Feld; Barnett S Kramer; Anita L Sabichi; Sandra L Wong; Andrew S Artz
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

10.  Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin.

Authors:  Simon Parker; Eliza Gil; Patricia Hewitt; Katherine Ward; Yasmin Reyal; Sasha Wilson; Jessica Manson
Journal:  BMC Infect Dis       Date:  2014-02-22       Impact factor: 3.090
  10 in total
  1 in total

1.  Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand.

Authors:  Philip Yi Choi; Eileen Merriman; Ashwini Bennett; Anoop K Enjeti; Chee Wee Tan; Isaac Goncalves; Danny Hsu; Robert Bird
Journal:  Med J Aust       Date:  2021-10-10       Impact factor: 12.776
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.